Beta Bionics, Inc.

NASDAQ:BBNX

Medical - Equipment & Services

Healthcare
$14.33 +3.18%

+$0.42 today

Market cap
$644.70M
Beta
3.39
P/E (TTM)
-9.1
EPS (TTM)
-$1.50
52W Low $8.80High $32.71

Volume 1.38M

Average 0.99M

BBNX EPS (Diluted)

Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.

Beta Bionics, Inc.NASDAQ: BBNX

EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026

EPS (Diluted) remains negative

Q1 FY2026 EPS (Diluted) was -$0.49, compared with -$0.93 a year earlier. Trailing-twelve-month EPS (Diluted) was -$1.51.

Context

  • EPS (Diluted) grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Diluted) reaches the consensus estimate from 7 analysts of -$2.04 (-13.0%) for the fiscal year ending Dec 2026, a slowdown from the +79.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.49-63.3% QoQ
Last fiscal yearDec 2025
-$1.81+79.0% YoY
LTMMar 2026
-$1.51+53.3% YoY
EPS (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+47.3%-49.0%-96.3 pp
1 year+79.0%-13.0%-91.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Diluted) history

USD · from the income statement

Latest · FY2025
(1.81) USD
Year-over-year change
+79.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Diluted) vs competitors

How BBNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +53.3% is the 4th highest of 7, against a peer median of +56.1%.
BBNX Competitors
EPS (Diluted) for BBNX and competitors
Company Period LTM YoY 3-year CAGR
NVONovo Nordisk A/SLTM Jun 2026DKK 26.19 DKK+5.0%+23.5%
PODDInsulet CorporationLTM Jun 2026$5.35 USD+62.6%+275.4%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$2.58 USD+463.4%—
DXCMDexCom, Inc.LTM Jun 2026$2.53 USD+75.7%+37.7%
MNKDMannKind CorporationLTM Mar 2026-$0.08 USD-175.4%—
MMEDMiniMed Group, Inc. Common StockLTM Jul 2026-$1.1 USD——
TNDMTandem Diabetes Care, Inc.LTM Mar 2026-$1.4 USD+49.7%—
BBNXBeta Bionics, Inc.LTM Mar 2026-$1.51 USD+53.3%—
Peer median (excluding BBNX) —+56.1%+37.7%

Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue179K12M65.12M100.25M
Cost of Revenue05.69M29.24M44.71M
Gross Profit179K6.31M35.89M55.54M
Gross Margin100.0%52.6%55.1%55.4%
Research & Development31.43M17.94M26.18M34.79M
Selling, General & Admin33.5M24.22M54.96M92.43M
Operating Expenses66.02M42.16M81.14M127.22M
Depreciation & Amortization1.35M1.23M1.15M2.88M
EBITDA(63.4M)(42.87M)(53.61M)(70.32M)
EBITDA Margin-35418.4%-357.4%-82.3%-70.1%
Operating Income(65.84M)(35.85M)(45.25M)(71.68M)
Operating Margin-36784.4%-298.9%-69.5%-71.5%
Interest Income196K1.78M3.91M10.93M
Interest Expense14K000
Other Income / Expenses1.09M(8.25M)(9.51M)(1.52M)
Income Before Tax(64.75M)(44.1M)(54.76M)(73.2M)
Pre-Tax Margin-36173.7%-367.6%-84.1%-73.0%
Income Tax Expense0001K
Net Income(64.75M)(44.1M)(54.76M)(73.2M)
Net Margin-36173.7%-367.6%-84.1%-73.0%
EPS (Basic)(12.96)(8.31)(8.60)(1.81)
EPS (Diluted)(12.96)(8.31)(8.60)(1.81)
Weighted Avg Shares5M5.3M6.37M40.53M
Weighted Avg Shares (Diluted)5M5.3M6.37M40.53M

Beta Bionics, Inc.

NASDAQ:BBNX

Intrinsic Alpha fair value

Locked

Current Price

$14.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.